Jascha Blobel, PhD, is working for more than 10 years in the drug discovery industry. He is co-founder and CEO of Molomics, a biotech that explores the integration of Artificial Intelligence with teams to design more efficacious and safer therapeutics. Molomics internal programs focus on Parkinson’s Disease. Previously, Jascha was the product manager of a biotech developing cheminformatics solutions. Jascha received his Masters from the University of Munich and his PhD from the Institute for Research in Biomedicine, Barcelona, for work related to protein structures. During his PhD, he published articles with research teams from Spain, Sweden, Germany and China.